Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Amgen told investors it is entering year-end with strong commercial momentum, reporting 10% revenue growth through the first nine months (ending Sept.) driven by 11% product sales growth and 14% volume growth. Management noted 12 products growing double-digits, 14 products annualizing at >$1 billion, and 16 products with double-digit growth in Q3, while flagging they are successfully navigating a full year of DMAb competition on Prolia and XGEVA — underscoring sustained top-line strength and continued investment across its four therapeutic areas.

Analysis

Market structure: Amgen (AMGN) benefits from broad diversification — 12 products growing double-digits and 14 >$1bn reduce single-product concentration risk even as denosumab (Prolia/XGEVA) faces a full year of DMAb competition. Expect pricing pressure and share loss in the bone franchise over 6–18 months, but net-demand appears strong (14% volume growth YTD) so near-term revenue resilience should limit downside to single-digit EPS hits absent wider reimbursement shocks. Broader winners include CMOs and reagent suppliers servicing high-volume biologics; losers are small-cap, single-product osteoporosis plays and any low-margin biosimilar entrants lacking scale.

Risk assessment: Tail risks include an adverse safety/regulatory development on a high-revenue product, accelerated biosimilar approvals, or a major manufacturing outage; each could inflict >15% downside on AMGN over 3–12 months. Immediate (days) risk is sentiment-driven around conference/quarterly commentary; short-term (weeks–months) risk centers on competitive uptake of DMAb and payer formulary shifts; long-term (years) risk is patent cliffs and failed late-stage programs. Hidden dependencies: reimbursement negotiations (PBMs/insurers) and China/EM market access can swing volumes by ±5–10% quickly. Key catalysts: Q4 earnings (Feb 2026), FDA/EMA biosimilar rulings, and payer guideline updates in next 90 days.

Trade implications: Tactical long: establish a 2–3% long position in AMGN, targeting 12–18% upside over 3–9 months, stop -8% on revenue miss >5% or guidance cut; buy Feb 2026 1–3 month call spreads to cap cost if expecting upside into earnings. Pair trade: long AMGN (2%) / short a specialty osteoporosis pure-play (~1%) or small-cap biosimilar hopefuls — if specific shorts required, favor names with >50% revenue tied to a single product (avoid naming without portfolio fit). Rotate into large-cap diversified biopharma and underweight small-cap specialty biotech for 3–12 months while implied vols remain below sector 90-day median.

Contrarian angles: The market may overstate DMAb impact — if Amgen retains even 60–70% of pre-competition volumes and reallocates marketing, EPS impact could be <5% and valuation support holds; consensus misses cross-selling upside from accelerating non-bone franchises. Historical parallel: big biotechs (e.g., JNJ, PFE) absorbed franchise-specific competition with limited multiple contraction when pipeline/scale offset losses. Unintended consequence: aggressive defense (price cuts, rebates) could compress margins and create short-term weakness, presenting a tactical entry opportunity if drawdown >10% on no-guidance-change.

Key Decisions for Investors

• Establish a 2–3% long position in AMGN (ticker: AMGN) within 2–4 weeks; target 12–18% upside over 3–9 months and implement an 8% hard stop if quarterly revenue misses consensus by >5% or management cuts FY guidance.
• Buy a Feb 2026 call spread on AMGN (debit call spread sized to 1–2% notional of portfolio) to capture upside into Q4 results (expected Feb 2026); select strikes ~8–12% above spot to limit premium and time decay exposure.
• Implement a relative-value pair: long AMGN (2% weight) and short a single-product small-cap biotech (1% weight) with >50% revenue dependence on osteoporosis or single biologic; close pair if AMGN underperforms by >7% on non-fundamental news or if short candidate reports positive pivotal data.
• Reduce small-cap specialty biotech exposure by 150–300 bps and reallocate to large-cap diversified biopharma (AMGN, JNJ, PFE) over the next 30 days to hedge biosimilar/regulatory concentration risk; reassess after Feb 2026 earnings and any biosimilar rulings.
• Monitor three specific triggers in the next 60 days before scaling: (1) any FDA/EMA decisions on denosumab biosimilars, (2) PBM/formulary guidance changes affecting Prolia/XGEVA reimbursement, and (3) AMGN’s Feb 2026 guidance — increase position if guidance is maintained and volume growth persists, reduce if guidance cut >3%.